[1]沈沛阳,孔祥斌,周立军,等.康柏西普对糖尿病黄斑水肿患者黄斑区视网膜微循环的作用：基于光学相干断层扫描血管成像（OCTA）的评价[J].眼科新进展,2019,39(11):1056-1059.[doi:10.13389/j.cnki.rao.2019.0242]
　SHEN Pei-Yang,KONG Xiang-Bin,ZHOU Li-Jun,et al.Analysis of the macular retinal microcirculation after intravitreal injection of Conbercept in eyes with diabetic macular edema based on optical coherence tomography angiography[J].Recent Advances in Ophthalmology,2019,39(11):1056-1059.[doi:10.13389/j.cnki.rao.2019.0242]
点击复制

康柏西普对糖尿病黄斑水肿患者黄斑区视网膜微循环的作用：基于光学相干断层扫描血管成像（OCTA）的评价/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年11期
页码:
1056-1059
栏目:
应用研究
出版日期:
2019-11-05

文章信息/Info

Title:
Analysis of the macular retinal microcirculation after intravitreal injection of Conbercept in eyes with diabetic macular edema based on optical coherence tomography angiography
作者:
沈沛阳; 孔祥斌; 周立军; 苏鹏; 黄玉娟; 周怀胜; 陆晓和
510282　广东省广州市，南方医科大学珠江医院眼科（沈沛阳，陆晓和）；528000　广东省佛山市，佛山市第二人民医院（南方医科大学附属佛山医院）（沈沛阳，孔祥斌，周立军，苏鹏，黄玉娟，周怀胜）
Author(s):
SHEN Pei-Yang; KONG Xiang-Bin; ZHOU Li-Jun; SU Peng; HUANG Yu-Juan; ZHOU Huai-Sheng; LU Xiao-He
Department of Ophthalmology，Zhujiang Hospital of Southern Medical University （SHEN Pei-Yang，LU Xiao-He），Guangzhou 510282，Guangdong Province，China；Department of Ophthalmology，the Second People’s Hospital of Foshan （Affiliated Foshan Hospital of Southern Medical University） （SHEN Pei-Yang，KONG Xiang-Bin，ZHOU Li-Jun，SU Peng，HUANG Yu-Juan，ZHOU Huai-Sheng），Foshan 528000，Guangdong Province，China
关键词:
光学相干断层扫描血管成像; 康柏西普; 糖尿病黄斑水肿
Keywords:
optical coherence tomography angiography; spectral-domain optical coherence tomography; Conbercept; diabetic macular edema
分类号:
R776.1
DOI:
10.13389/j.cnki.rao.2019.0242
文献标志码:
A
摘要:
目的　应用光学相干断层扫描血管成像（OCTA）评价康柏西普对糖尿病黄斑水肿患者黄斑区视网膜微循环的影响。方法　回顾性分析17例（20眼）糖尿病黄斑水肿患者资料，所有患者均行玻璃体内注射康柏西普治疗。分析比较术前和术后1个月患者最佳矫正视力、视网膜中央厚度和OCTA测得的视网膜各参数。结果　所有患者抗VEGF治疗后随访1个月，效果良好；最佳矫正视力(logMAR)从术前的 0.66±0.23提高到0.50±0.26；视网膜中央厚度从术前的（497.2±71.6）μm降至（341.3±54.2）μm，差异均有统计学意义（均为P<0.05）。OCTA测量的无血管区面积和各毛细血管层的黄斑区血管密度等参数在抗VEGF治疗前后差异均无统计学意义（均为 P>0.05）。结论　玻璃体内注射康柏西普能够有效减轻黄斑水肿、提高视力，且不会加剧黄斑区无灌注程度，不会加重黄斑区微循环障碍。
Abstract:
Objective　To observe the clinical therapeutic efficacy of a single intravitreal injection of Conbercept for diabetic macular edema，and to evaluate the macular perfusion status using optical coherence tomography angiography （OCTA）.Methods　A retrospective study was conducted in 17 patients （20 eyes） and the clinical data were reviewed and analyzed.All patients received the intravitreal injection of Conbercept，and underwent best-corrected visual acuity （BCVA），central retinal thickness and OCTA measurements before and one month after intravitreal injection.Results　The study evaluated 20 eyes of 17 patients with diabetic macular edema ［mean (67.2±11.6)years old］.At 1 month after injection，the logarithm of minimum angle of resolution （logMAR） BCVA significantly improved from (0.66±0.23)logMAR to (0.50±0.26)logMAR （P<0.05），and the average central retinal thickness decreased significantly from (497.2±71.6)μm to (341.3±54.2)μm （P<0.05）.No significant difference was found with respect to the foveal avascular zone area and vessel density in the fovea and parafovea （all P>0.05）.Conclusion　This study demonstrated that intravitreal injection of Conbercept can alleviate the diabetic macular edema and restore the visual acuity.The foveal avascular zone area and vessel density remained stable after a single intravitreal anti-VEGF injection.

参考文献/References:

［1］　MOHAMED Q，GILLIES M C，WONG T Y.Management of diabetic retinopathy：a systematic review［J］.JAMA，2007，298（8）：902-916.
［2］　ZHANG X，SAADDINE J B，CHOU C F，COTCH M F，CHENG Y J，GEISS L S，et al.Prevalence of diabetic retinopathy in the United States，2005-2008［J］.JAMA，2010，304（6）：649-656.
［3］　XIE X W，XU L，WANG Y X，JONAS J B.Prevalence and associated factors of diabetic retinopathy.The Beijing Eye Study 2006［J］.Graefes Arch Clin Exp Ophthalmol，2008，246（11）：1519-1526.
［4］　WANG F H，LIANG Y B，ZHANG F，WANG J J，WEI W B，TAO Q S，et al.Prevalence of diabetic retinopathy in rural China：the Handan Eye Study［J］.Ophthalmology，2009，116（3）：461-467.
［5］　YAU J W，ROGERS S L，KAWASAKI R，LAMOUREUX E L，KOWALSKI J W，BEK T，et al.Global prevalence and major risk factors of diabetic retinopathy［J］.Diabetes Care，2012，35（3）：556-564.
［6］　NGUYEN Q D，BROWN D M，MARCUS D M，BOYER D S，PATEL S，FEINER L，et al.Ranibizumab for diabetic macular edema：results from 2 phase Ⅲ randomized trials：RISE and RIDE［J］.Ophthalmology，2012，119（4）：789-801.
［7］　LI X，XU G，WANG Y，XU X，LIU X，TANG S，et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration：results from a 12-month randomized phase 2 study：AURORA study［J］.Ophthalmology，2014，121（9）：1740-1747.
［8］　SU L，REN X，WEI H，ZHAO L，ZHANG X，LIU J，et al.Intravitreal conbercept （Kh902） for surgical treatment of severe proliferative diabetic retinopathy［J］.Retina，2016，36（5）：938-943.
［9］　SPAIDE R F，KLANCNIK J M，COONEY M J.Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography［J］.JAMA Ophthalmol，2015，133（1）：45-50.
［10］　MILLER J W，LE COUTER J，STRAUSS E C，FERRARA N.Vascular endothelial growth factor a in intraocular vascular disease［J］.Ophthalmology，2013，120（1）：106-114.
［11］　OWEN L A，HARTNETT M E.Soluble mediators of diabetic macular edema：the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema［J］.Curr Diab Rep，2013，13（4）：476-480.
［12］　CAMPOCHIARO P A，BHISITKUL R B，SHAPIRO H，RUBIO R G.Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion［J］.Ophthalmology，2013，120（4）：795-802.
［13］　CAMPOCHIARO P A，WYKOFF C C，SHAPIRO H，RUBIO R G，EHRLICH J S.Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema［J］.Ophthalmology，2014，121（9）：1783-1789.
［14］　SIM D A，KEANE P A，ZARRANZ-VENTURA J，BUNCE C V，FRUTTIGER M，PATEL P J，et al.Predictive factors for the progression of diabetic macular ischemia［J］.Am J Ophthalmol，2013，156（4）：684-692.
［15］　CHEN E，HSU J，PARK C H.Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema［J］.Ophthalmic Surg Lasers Imaging，2009，40（1）：68-70.
［16］　COMYN O，SIVAPRASAD S，PETO T，NEVEU M M，HOLDER G E，XING W，et al.A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema （the LUCIDATE study）［J］.Am J Ophthalmol，2014，157（5）：960-970.
［17］　BABA T，KAKISU M，NIZAWA T，OSHITARI T，YAMAMOTO S.Superficial foveal avascular zone determined by optical coherence tomography angiography before and after macular hole surgery［J］.Retina，2017，37（3）：444-450.
［18］　MICHAELIDES M，FRASER-BELL S，HAMILTON R，KAINES A，EGAN C，BUNCE C，et al.Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema （Bolt Study）：Report 1［J］.Retina，2010，30（5）：781-786.
［19］　NESPER P L，ROBERTS P K，ONISHI A C，CHAI H，LIU L，JAMPOL L M，et al.Quantifying microvascular abnormalities with increasing severity of diabetic retinopathy using optical coherence tomography angiography［J］.Invest Ophthalmol Vis Sci，2017，58（6）：BIO307-BIO315.
［20］　ATTAALLAH H R，MOHAMED A A M，ALI M A.Macular vessels density in diabetic retinopathy：quantitative assessment using optical coherence tomography angiography［J］.Int Ophthalmol，2019，39（8）：1845-1859.
［21］　FALAVARJANI K G，IAFE N A，VELEZ F G，SCHWARTZ S D，SADDA S R，SARRAF D，et al.Optical coherence tomography angiography of the fovea in children born preterm［J］.Retina，2017，37（12）：2289-2294.

相似文献/References:

[1]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(11):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[2]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(11):172.[doi:10.13389/j.cnki.rao.2016.0047]
[3]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(11):471.[doi:10.13389/j.cnki.rao.2016.0126]
[4]董秀芬,钟华.Angio-OCT在眼科疾病临床应用中研究进展[J].眼科新进展,2016,36(7):697.[doi:10.13389/j.cnki.rao.2016.0185]
　DONG Xiu-Fen,ZHONG Hua.Application of Angio-OCT in ophthalmic diseases[J].Recent Advances in Ophthalmology,2016,36(11):697.[doi:10.13389/j.cnki.rao.2016.0185]
[5]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(11):725.[doi:10.13389/j.cnki.rao.2016.0192]
[6]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(11):751.[doi:10.13389/j.cnki.rao.2016.0200]
[7]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[8]吴若欣,徐洁慧,温积全,等.玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响[J].眼科新进展,2016,36(12):1172.[doi:10.13389/j.cnki.rao.2016.0312]
　WU Ruo-Xin,XU Jie-Hui,WEN Ji-Quan,et al.Effects of intravitreal conbercept injections on choroidal thickness in exudative age-related macular degeneration[J].Recent Advances in Ophthalmology,2016,36(11):1172.[doi:10.13389/j.cnki.rao.2016.0312]
[9]刘青,艾明.光学相干断层扫描血管成像（OCTA）和荧光素血管造影（FFA）对比观察增生型糖尿病视网膜病变（PDR）[J].眼科新进展,2017,37(1):052.[doi:10.13389/j.cnki.rao.2017.0014]
　LIU Qing,AI Ming.Characteristics of proliferative diabetic retinopathy observed by optical coherence tomography angiography and fundus fluorescein angiography[J].Recent Advances in Ophthalmology,2017,37(11):052.[doi:10.13389/j.cnki.rao.2017.0014]
[10]薛鹏程,游志鹏,付书华,等.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变（PDR）的疗效分析[J].眼科新进展,2017,37(5):458.[doi:10.13389/j.cnki.rao.2017.0116]
　XUE Peng-Cheng,YOU Zhi-Peng,FU Shu-Hua,et al.Preoperative and intraoperative adjunctive intravitreal conbercept in 23G vitrectomy for proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(11):458.[doi:10.13389/j.cnki.rao.2017.0116]
[11]马若璇,冉振龙,张月玲,等.玻璃体内注射康柏西普对糖尿病性黄斑水肿患者黄斑区视网膜血管密度和中心凹无血管区面积的影响[J].眼科新进展,2020,40(4):365.[doi:10.13389/j.cnki.rao.2020.0084]
　MA Ruoxuan,RAN Zhenlong,ZHANG Yueling,et al.Effect of intravitreal injection of Conbercept for treatment of diabetic macular edema on retinal vessel density at macular region and foveal avascular zone area[J].Recent Advances in Ophthalmology,2020,40(11):365.[doi:10.13389/j.cnki.rao.2020.0084]
[12]冉振龙,张海江,陈强,等.康柏西普联合黄斑格栅光凝治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2020,40(9):845.[doi:10.13389/j.cnki.rao.2020.0192]
　RAN Zhenlong,ZHANG Haijiang,CHEN Qiang,et al.The effect of conbercept combined with macular grid photocoagulation on diabetic macular edema[J].Recent Advances in Ophthalmology,2020,40(11):845.[doi:10.13389/j.cnki.rao.2020.0192]

备注/Memo

备注/Memo:
2019广东省医学科学技术研究基金（编号：B2019079）；广东省佛山市博士后专项基金（编号：214901）；2017白求恩·默克糖尿病研究基金临床研究项目
更新日期/Last Update: 2019-11-18